Phase 1 N=13 PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
HIV Infections
Primary: Frequency of Grade 3 or Higher Adverse Events — 0 number of occurrences
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=52 Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
Neoplasms
Primary: Part 1A: Number of Participants Experiencing Dose Limiting Toxicity (DLT) — 0; 1; 0; 0 Participants
Phase 1 N=12 Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Pregnancy · Contraception
Primary: Part 1: Serum Medroxyprogesterone Acetate (MPA) Concentration at Day 1 — 0.36; 0.67 nanograms (ng)/milliliter (mL)
Phase 1 N=45 Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
Covid19 · Severe Acute Respiratory Syndrome · SARS-CoV-2 Infection
Primary: Number of at Least Possibly Related Grade 3 Adverse Events (AE) and Serious Adverse Events (SAE) — 0; 1; 0; 0 adverse events
Phase 1 N=28 CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Multiple Myeloma
Primary: Number of Participants Evaluated for Vaccine Safety — 13; 15 Participants
Phase 1 N=20 The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
Drug Drug Interaction
Primary: Cmax of Givinostat, Following Single Doses of the Parent Drug — 53.57; 75.35 ng/mL
Phase 1 N=37 A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate
Phase 1
Primary: Dose of Metoprolol Resulting in no Change in Mean Heart Rate Over 24 Hours (M24HR) — 10.04; 60.95; 147.91 mg
Phase 1 N=160 A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
Hepatitis B, Chronic
Primary: Part 1: Percentage of SAD Participants With Adverse Events (AEs) — 31.3; 25.0; 50.0; 25.0 percentage of participants
Phase 1 N=51 A Study of Mirikizumab (LY3074828) in Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=55 A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
Obesity
Primary: Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR) — -154.36; -134.68 kilocalories per day (kcal/day) — p=0.5733
Phase 1 N=14 Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation
Absorption; Chemicals
Primary: Total Drug Exposure. (Area Under the Curve to Infinity [AUC(Inf)] — 674.9; 134.76 ng*h/ml
Phase 1 N=52 A Study of Tirzepatide (LY3298176) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide — 113000; 109000 nanograms*hours per milliliter(ng*hr/mL)
Phase 1 N=15 Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Advanced Non CNS Tumors
Primary: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 0.0; 0.0; 100.0; 100.0 Percent of participants
Phase 1 N=55 Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants
Gastrointestinal Diseases
Primary: Maximum Observed Post Dose Concentration (Cmax) — 483; 514 Nanograms per milliliter
Phase 1 N=29 A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Non-small Cell Lung Cancer
Primary: Phase 1a: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants